<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05026112</url>
  </required_header>
  <id_info>
    <org_study_id>143656</org_study_id>
    <nct_id>NCT05026112</nct_id>
  </id_info>
  <brief_title>The Arrhythmogenic Potential of Midwall Septal Fibrosis in Dilated Cardiomyopathy</brief_title>
  <official_title>The Arrhythmogenic Potential of Midwall Septal Fibrosis in Dilated Cardiomyopathy: a Combined ECGi and CMR Investigative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Midwall septal fibrosis (MSF) is a common structural abnormality in non-ischaemic dilated&#xD;
      cardiomyopathy (DCM) and its presence is believed to increase the risk of malignant&#xD;
      ventricular arrhythmias (VA) but the mechanism of arrhythmogenicity is not known. This is&#xD;
      especially relevant in DCM patients with MSF and mid-range left ventricular ejection fraction&#xD;
      (EF) as they do not currently fulfill criteria for a primary prevention implantable&#xD;
      cardioverter defibrillator.&#xD;
&#xD;
      Access to the epicardium for electric measurements can enhance our understanding of&#xD;
      arrhythmogenicity in DCM but direct epicardial access is invasive. Instead, we will&#xD;
      noninvasively combine high resolution 256-lead ECG imaging (ECGi) and latest generation&#xD;
      cardiovascular magnetic resonance (CMR) to study the hearts of 60 DCM patients with and&#xD;
      without MSF regardless of the EF, and 60 matched healthy volunteers. We recently invented the&#xD;
      re-usable and CMR-safe SMART-ECGi vest technology for this purpose. Using supercomputers, we&#xD;
      will fuse the collected ECGi/CMR data and run electromechanical simulations of whole-heart&#xD;
      activation to non-invasively measure each participant's personalised risk of malignant VA&#xD;
      induction.&#xD;
&#xD;
      By panoramically mapping the DCM heart in a single beat, we will reveal how MSF perturbs the&#xD;
      cardiac activation front potentially leading to life-threatening VA. This has the potential&#xD;
      to change the way we risk stratify patients with DCM&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will be collecting ECG-Imaging data, cardiac MRI scan, blood sampling, clinicodemographic&#xD;
      data collection, and resting 12-lead ECG on each participant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The relationship between the electrical and structural substrate in DCM</measure>
    <time_frame>2 years</time_frame>
    <description>Describe the relationship between the electrical and structural substrate in DCM across the spectrum of left ventricular dysfunction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of epicardial activation and conduction patterns via ECGi</measure>
    <time_frame>2 years</time_frame>
    <description>Comparison of MSF+DCM, MSF-DCM and controls in terms of epicardial activation and conduction patterns (via ECGi)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of MSF+DCM, MSF-DCM and controls' electromechanical function of the heart via modelling</measure>
    <time_frame>2 years</time_frame>
    <description>To compare MSF+DCM, MSF-DCM and controls in terms of Electromechanical function of the heart (via 4-dimensional computational models)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personalised simulation of risk of malignant ventricular arrhythmia</measure>
    <time_frame>2 years</time_frame>
    <description>Applying and exploring simulation methodology to establish predictions for likely propensity to malignant VA (personalised simulations of risk) between MSF+DCM, MSF-DCM and controls groups</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>DCM with MSF (MSF+)</arm_group_label>
    <description>Patients with dilated cardiomyopathy and midwall septal fibrosis identified in a previous cardiac MRI scan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DCM without MSF (MSF-)</arm_group_label>
    <description>Patients with dilated cardiomyopathy but without midwall septal fibrosis on previous cardiac MRI scan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control - MSF+</arm_group_label>
    <description>Control healthy volunteers (HV) to the MSF+ cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control - MSF-</arm_group_label>
    <description>Control healthy volunteers (HV) to the MSF- cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ECG-Imaging</intervention_name>
    <description>ECG imaging acquisition</description>
    <arm_group_label>Control - MSF+</arm_group_label>
    <arm_group_label>Control - MSF-</arm_group_label>
    <arm_group_label>DCM with MSF (MSF+)</arm_group_label>
    <arm_group_label>DCM without MSF (MSF-)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac MRI scan</intervention_name>
    <description>Cardiac MRI scan</description>
    <arm_group_label>Control - MSF+</arm_group_label>
    <arm_group_label>Control - MSF-</arm_group_label>
    <arm_group_label>DCM with MSF (MSF+)</arm_group_label>
    <arm_group_label>DCM without MSF (MSF-)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample collection procedure - for storage of DNA, RNA, small molecule analysis (e.g.&#xD;
      proteomics and transcriptomics) and blood cells for human induced pluripotent stem cells&#xD;
&#xD;
      Urine sample collection for small molecule analysis&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with dilated cardiomyopathy, with and without midwall septal fibrosis on previous&#xD;
        CMR&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults with dilated cardiomyopathy&#xD;
&#xD;
          -  With and without midwall septal fibrosis on previous CMR&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Needle-phobic patients that would preclude cannulation for contrast injection and&#xD;
             blood taking&#xD;
&#xD;
          -  anyone unwilling to consent&#xD;
&#xD;
          -  anyone with a conventional contraindication for CMR&#xD;
&#xD;
          -  anyone with any condition precluding full participation in the study such as DCM&#xD;
             patients with infarct-pattern LGE, or subepicardial LGE or non-septal midwall fibrosis&#xD;
             (we will not exclude participants with small volume right ventricular insertion point&#xD;
             LGE).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriella Captur, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fiona Chan, MBBS</last_name>
    <phone>02076705702</phone>
    <email>f.chan@ucl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gabriella Captur, PhD</last_name>
    <phone>02076705702</phone>
    <email>gabriella.captur@ucl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Free Hospital NHS Trust (RFH)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Fiona Chan, MBBS</last_name>
      <phone>02076705702</phone>
      <email>f.chan@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Dr Gabriella Captur, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

